We describe a challenging case of a patient with MBL-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time kill curves showed that this triple antibiotic combination at 1 X MIC was strongly synergic after 8 hours, achieving 99.9% killing, and maintaining this until 48 hours.
Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis
Grossi, PaoloUltimo
Membro del Collaboration Group
2021-01-01
Abstract
We describe a challenging case of a patient with MBL-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time kill curves showed that this triple antibiotic combination at 1 X MIC was strongly synergic after 8 hours, achieving 99.9% killing, and maintaining this until 48 hours.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.